Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose Of Review: The identification of STAT1 gain-of-function (GOF) in 2011 and STAT3 GOF in 2014 has advanced our understanding of the host immunity along the JAK/STAT pathway and allowed targeted treatment approaches. We review the clinical features and pathogenesis of STAT1 and STAT3 GOF and how this has shaped new approaches to therapy.
Recent Findings: STAT1 GOF, initially described in patients with chronic mucocutaneous candidiasis (CMC) and autoimmune thyroid disease, is now recognized to cause early-onset multisystem autoimmunity and a range of infections. STAT3 GOF comprises mostly lymphoproliferation and autoimmunity but also with varying severity, including some with life threatening organ dysfunction. Treatment has evolved along with the understanding of the pathogenesis, with patients now receiving JAK inhibition to block upstream of the STAT defect with good response in autoimmunity and CMC in STAT1 GOF. Blockade of IL-6 signaling has also been used in STAT3 GOF. Hematopoietic cell transplantation had initial poor outcomes, but outcomes are now improving with focus on the control of inflammation pretransplant.
Summary: Understanding the pathogenesis of STAT1 and STAT3 GOF has allowed great recent advancements in therapy, but many questions remain as to the best approach to therapy for each patient's clinical presentation as well as the durability of these therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573110 | PMC |
| http://dx.doi.org/10.1097/ACI.0000000000001039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical features and immunotherapy for children with loss-of-function/gain-of-function mutations in the gene: an analysis of 10 cases].
Zhongguo Dang Dai Er Ke Za Zhi
August 2025
Department of Pediatrics, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Objectives: To investigate the clinical features of children with gene mutations, and to explore corresponding immunotherapy strategies.
Methods: A retrospective analysis was performed for the clinical data of 10 children with gene mutations who were admitted to the Department of Pediatrics of the First Affiliated Hospital of Guangzhou Medical University, from October 2015 to October 2024. Exploratory immunotherapy was implemented in some refractory cases, and the changes in symptoms, imaging manifestations, and cytokine levels were assessed after treatment.
Successful anti-IL-6 treatment for interstitial lung disease associated with STAT3 gain-of-function: a case report and literature review.
Front Pediatr
July 2025
Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Autosomal dominant gain-of-function (GOF) variants in the signal transducer and activator of transcription 3 () result in an inborn error of immunity characterized by multi-organ autoimmunity and lymphoproliferation. In this study, we retrospectively analyzed a rare case of GOF mutation with thrombocytopenia, immunoglobulin deficiency, and recurrent respiratory infections. Whole-exome sequencing revealed a heterozygous mutation (c.
View Article and Find Full Text PDFEndocrinopathies in children with inborn errors of immunity: a single-center experience.
J Pediatr Endocrinol Metab
July 2025
Department of Pediatric Allergy and Immunology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Türkiye.
Objectives: Inborn errors of immunity (IEI) are a diverse group of genetically inherited disorders. We aimed to summarize and discuss endocrinopathies in children with IEI.
Methods: This study included 84 IEI patients evaluated between September 2019 and September 2023.
Dominant-Negative Versus Gain-of-Function STAT3 Defects: A Systematic Review on Epidemiological, Clinical, Immunological, and Molecular Aspects.
J Allergy Clin Immunol Pract
June 2025
Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran. Electronic address:
Background: Germline signal transducer and activator of transcription 3 (STAT3) mutations cause 2 distinct syndromes with predominant infectious or autoimmune phenotype.
Objective: The objective of this study is to compile literature reports on gain-of-function (GOF) and dominant-negative (DN) mutations in the STAT3.
Methods: We searched 3 main databases including PubMed, Scopus, and Web of Science from 1990 to 2023.
Pulmonary Aspergillosis and Low HIES Score in a Family with STAT3 N-Terminal Domain Mutation.
J Clin Immunol
February 2025
Faculty of Biochemistry and Molecular Medicine, University of Oulu, Aapistie 7, Oulu, Finland.
Signal transducer and activator of transcription 3 (STAT3) plays a key role in leukocytic and non-leukocytic cells. Germ line mutations in STAT3, which are mainly found in the SH2, DNA binding and transactivation domains, can be loss- or gain-of-function (LOF and GOF). STAT3 N-terminal domain (NTD) mutations are rare, and their biological effects remain incompletely understood.
View Article and Find Full Text PDF